4th SFCNS Congress
Preliminary Program

Swiss Federation of Clinical Neuro-Societies

October 23 - 25, 2019
SwissTech Convention Center, EPFL
Lausanne

sfcns2019.congress-imk.ch
4th SFCNS Congress

It is our great pleasure to announce the 4th congress of the Swiss Federation of Clinical Neuro-Societies (SFCNS), which will take place in Lausanne at the SwissTech Convention Center from October 23 to 25, 2019.

Starting with the 6 original (founding) societies (Neurology, Neurosurgery, Neuroradiology, Neuropediatrics, Neuropathology and Clinical Neurophysiology), the federation has over the last years grown to encompass most if not all societies and individuals involved in managing diseases of the central nervous system in Switzerland.

Ever since its foundation, the SFCNS has undertaken efforts to improve the quality and visibility of Swiss neuroscience – locally, nationally and internationally. This has been done with great success by promoting clinical excellence, scientific research as well as political lobbying. Further, collaboration and exchange between the various clinical neurosocieties which form the SFCNS have been promoted.

The SFCNS has thus successfully been active in the creation and certification of world-class stroke centers as well as in defining the criteria by which Highly Specialized Medicine (HSM) is to be practiced in Switzerland in the domain of clinical neurosciences. Since its founding in 2009 and the first congress in 2010, the SFCNS has continuously grown and expanded its success, vision and influence. In addition to the congress, the Society has successfully developed summer schools to attract its members and further established the Journal Clinical and Translational Neuroscience as its own vehicle for scientific publications.

One of the central factors for the success of the SFCNS is its triennial congress, which represents a unique encounter between not just the various societies which form its core but also of adjacent specialties that will contribute to our common future. Thus, it is exceedingly important that the congress does not only represent the various member societies, but that it also has a spirit of its own.

The fourth congress of the SFCNS is this time not just held in any congress center, but in the heart of Swiss technological innovation at the SwissTech Convention Center, which is located in the heart of the campus of the Ecole Polytechnique Fedele de Lausanne (EPFL). This represents a breakout from the previous locations Basel and Montreux and is of extreme importance to us all, since clinical neuroscience has benefited from advances in technology since its inception. Further, leaders in neuroscience very often contribute to technological developments themselves. Therefore, additionally to the traditional neuro-science participants we will see participants from fields of technologies such as basic neuroimaging, robotics and artificial intelligence that have contributed and will further contribute to the definition of the way clinical neuroscientists work over the next century.

The congress program is extremely rich and varied and proposes a multitude of formats for presenting knowledge and advances in neuroscientific areas: the days will start with plenary sessions that will be followed by satellite symposia and parallel sessions devoted to topics of clinical and scientific interest.

We hope that you will join us in Lausanne for this exciting event and that you will have as much pleasure attending the congress as we have in organizing it.

Prof. Karl Olof Lövblad, MD
Congress President

Prof. Karl Schaller, MD
President SFCNS
### Plenary Session

#### Keynote Lecture
Chair: C. Bassetti, Bern, CH

**Presence hallucinations: from epilepsy and Parkinson's disease to neuroscience robotics**  
O. Blanke, Geneva, CH

### Plenary Session

#### Smarter Devices
Chair: K. Rösler, Bern und Basel, CH

**Sensing and computing bits in Edge AI: enabling technologies for future Human Avatars**  
A. Ionescu, Lausanne, CH

**Virtual reality approaches to study and improve cognitive and motor deficits after stroke**  
A. Serino, Lausanne, CH

**Mobile technologies for remote, patient driven neuro-monitoring and stimulation**  
W. Karlen, Zurich, CH

### General Assembly

#### Neurological Society (SNS)

### Parallel Sessions

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Satellite Symposium</strong></td>
<td>Novartis Pharma Schweiz AG</td>
<td>When progression takes over: novel treatment options for SPMS</td>
</tr>
<tr>
<td></td>
<td>Mitsubishi Tanabe Pharma GmbH</td>
<td></td>
</tr>
<tr>
<td><strong>Satellite Symposium</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Satellite Symposium</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Parallel Session</strong></td>
<td>Acute-Stroke</td>
<td></td>
</tr>
<tr>
<td><strong>Parallel Session</strong></td>
<td>Neuro-Intensive Care</td>
<td></td>
</tr>
<tr>
<td><strong>Parallel Session</strong></td>
<td>YouClin</td>
<td>Models of human memory – Part I</td>
</tr>
<tr>
<td><strong>Parallel Session</strong></td>
<td>Baasch-Medicus-Lecture</td>
<td>Neurosurgery/Neuroradiology</td>
</tr>
<tr>
<td><strong>Parallel Session</strong></td>
<td>Intraoperativ Neuromonitoring</td>
<td>YouClin</td>
</tr>
<tr>
<td><strong>Parallel Session</strong></td>
<td></td>
<td>Models of human memory – Part II</td>
</tr>
</tbody>
</table>
**Plenary Session**

**Neuroimmunology and Neuroinflammation Crosstalks**
Chairs: K. Do Cuénod, Lausanne; K. Nedeltchev, Aarau, CH

**Pediatric inflammatory brain diseases – overview and management**
S. Bigi, Bern, CH

**The T cell/phagocyte interface in neuroinflammation**
B. Becher, Zurich, CH

**Neuroinflammation and oxidative stress in schizophrenia pathophysiology: a translational approach**
K. Do Cuénod, Lausanne, CH

**Plenary Session**

**Low back pain - a global challenge**
Chairs: B. Tettenborn, St. Gallen; J. Fandino, Aarau, CH

**The burden of low back pain**
J. Petersen, Zurich, CH

**Added value of imaging in acute low back pain**
J. Van Goethem, Antwerpen, BE

**Sense and nonsense in lumbar spinal stenosis surgery**
A. Raabe, Bern, CH

**Convincing reasons for the conservative approach**
Susanne Hartmann-Fussenegger, St. Gallen
**PROGRAM**

**Friday, 25.10.2019 | 08:30-16:00**

### Plenary Session

**Dangerous Headache**

Chairs: A. Raabe, Bern; Ch. Stippich, Zurich; CH

**Dangerous headaches: not always hemorrhages**

A. Straube, Munich, DE

**Specific Imaging Strategies and Findings in Patients with Headaches**

O. Jansen, Kiel, DE

**Special aspects: CSF and vascular causes**

J. Beck, Freiburg, DE

---

<table>
<thead>
<tr>
<th>Parallel Session</th>
<th>Parallel Session</th>
<th>Parallel Session</th>
<th>IG-NOPPS</th>
<th>Symposium</th>
</tr>
</thead>
<tbody>
<tr>
<td>Imaging findings in patients with headache</td>
<td>Vertigo</td>
<td>YouClin</td>
<td>IG-NOPPS</td>
<td>OHBM Alpine Chapter</td>
</tr>
<tr>
<td>Satellite Symposium</td>
<td>Satellite Symposium</td>
<td>Satellite Symposium</td>
<td>IG-NOPPS</td>
<td>Symposium</td>
</tr>
<tr>
<td>Merck (Schweiz) AG</td>
<td>Eli Lilly Suisse (SA)</td>
<td></td>
<td>IG-NOPPS</td>
<td>OHBM Alpine Chapter</td>
</tr>
<tr>
<td>Parallel Session</td>
<td>Parallel Session</td>
<td>Parallel Session</td>
<td>IG-NOPPS</td>
<td>Symposium</td>
</tr>
<tr>
<td>Headache for Practitioners - case based</td>
<td>Behavior Neurology</td>
<td>EEG/Epilepsy</td>
<td>IG-NOPPS</td>
<td>OHBM Alpine Chapter</td>
</tr>
</tbody>
</table>

---

### Plenary Session

**Brain of the future**

Chair: K. Lövblad, Geneva; Andrea Rossetti, Lausanne, CH

**Neurology: “Eppur si muove”**

From a diagnostic to a therapeutic specialty

C. Bassetti, Bern, CH

**The prevention of stroke and Alzheimer's disease: the old and the new**

G. Frisoni, Geneva, CH

**Advances and Perspectives on the treatment of neurovascular diseases**

V. M. Pereira, Toronto, USA

**Neuroprosthetic technologies for restoring leg motor control after paralysis**

J. Bloch, Lausanne, CH
Rebif®/Rebif® multidose™/Rebif® RebiDose™ Interferon beta-1a ADNr

I: Patienten mit einem ersten klinischen, auf Multiple Sklerose (MS) hinweisenden neurologischen Ereignis bei Ausschluss anderer Diagnosen und glz. hohem Risiko für das Auftreten einer schubförmigen MS. Schubförmige MS.

D: i.Allg. 44 µg, dreimal pro Woche subkutan.


V: Thrombotische Mikroangiopathie (TMA), Thrombophlebitis, Krepitation, nicht abzutrennende Blasen, Angelegene pleurale Effusionen, kumulative Hyperthermie, Depression.

IA: Medikamente mit enger therapeutischer Breite

P: Rebif® 8.8 µg/0.2 ml und 22 µg/0.5 ml Fertigspritzen: 6 + 6 (Startpackung*); 22 µg/0.5 ml oder 44 µg/0.5 ml Fertigspritzen: je 12*. Rebif® multidose™ Patronen zu 66 µg/1.5 ml oder 132 µg/1.5 ml: je 4*. Rebif® RebiDose™ 8.8 µg/0.2 ml und 22 µg/0.5 ml Fertigpens: je 12*. (B) (*=kassenzulässig). Für detaillierte Informationen siehe www.swissmedicinfo.ch. JAN16


Merck (Schweiz) AG Chamerstrasse 174 CH-6301 Zug www.merck.ch
**Date**
October 23-25, 2019

**Venue**
SwissTech Convention Center  
Route Louis-Favre 2, 1024 Ecublens, CH  
www.stcc.ch

**Website**
sfcns2019.congress-imk.ch

**Scientific committee**
Prof. Karl-Olof Lövblad, MD, Geneva, Congress President  
Bigna Bölsterli, MD, Zurich  
Prof. Kim Do Cuénod, MD, Lausanne  
PD Barbara Goeggel Simonetti, MD, Bern/Bellinzona  
Harald F. Grossmann, Basel  
Prof. Doron Merkler, MD, Geneva  
Prof. Krassen Nedeltchev, MD, Aarau  
Prof. Andreas Raabe, MD, Bern  
Prof. Kai Rösler, MD, Bern und Basel  
Prof. Andrea Rossetti, MD, Lausanne  
Prof. Christoph Stippich, MD, Zurich  
Prof. Barbara Tettenborn, MD, St. Gallen  
Prof. Dimitri Van De Ville, PhD, Lausanne  
Prof. Sebastian Walther, MD, Bern  
Rebekka Zimmermann, MD, Bern

**Participating professional associations**
Swiss Association for Neurophysiological Diagnostic SFND/ASDN  
Association of neurosurgical nursing staff Switzerland IG-NOPPS with a separate one-day program on October 24, 2019.

<table>
<thead>
<tr>
<th>Registration fee</th>
<th>Early Bird until 15.09.2019</th>
<th>Regular from 16.09.2019</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Member physicians</strong></td>
<td>150.- 300.-</td>
<td>200.- 350.-</td>
</tr>
<tr>
<td><strong>Non-member physicians</strong></td>
<td>200.- 400.-</td>
<td>250.- 450.-</td>
</tr>
<tr>
<td>**Member residents, SAYN</td>
<td>SYNS</td>
<td>YouClin**</td>
</tr>
<tr>
<td><strong>Non-member residents</strong></td>
<td>70.- 140.-</td>
<td>90.- 180.-</td>
</tr>
<tr>
<td><strong>Students, MTM, PhD</strong></td>
<td>50.- 100.-</td>
<td>70.- 140.-</td>
</tr>
<tr>
<td>**SFND</td>
<td>IG-NOPPS**</td>
<td>50.-</td>
</tr>
</tbody>
</table>

* The registration fees IG-NOPPS for the congress are covered by the SSNS.  
Therefore the participation is free of charge.

**Registration**

**Cancellation policy**
IMK must be informed about cancellations in writing. Until 31.08.2019, 50% of the costs will be reimbursed. After 31.08.2019, no refunds will be made.

**Abstract Submission**
via congress website until **05.05.2019**

**Credits**
Credits will be requested from various societies.

**Professional Congress Organizer (PCO)**
IMK Institute for medicine and communication Ltd  
Münsterberg 1, CH-4001 Basel  
Phone: +41 61 271 35 51 | Fax: +41 61 271 33 38  
congress@imk.ch | www.imk.ch
The Swiss Federation of Clinical Neuro-Societies (SFCNS) was officially founded in 2009. First steps in that direction were taken at the Joint Meeting of six Clinical Neuroscience Societies in April 2008 in Montreux, which commemorated the centenary of the Swiss Neurological Society.

Following this great success and overwhelming approval, the Swiss Neurological Society (SNS), Swiss Society of Neurosurgery (SSNS), Swiss Society of Clinical Neurophysiology (SSNC), Swiss Society of Neuropaediatrics (SSNP), Swiss Society of Neuroradiology (SSNR), and Swiss Society of Neuropathology (SSNPath) decided to close ranks and form a Swiss Federation of Clinical Neuro-Societies (SFCNS) which marked the beginning of a new cooperative effort to strengthen the clinical neurosciences in Switzerland. The federation should formalise and structure the joint medico-political, educational and clinical research efforts.

Its further aim is to hold common meetings on a regular basis to facilitate mutual interactions and be open also to other medical groups pursuing clinical neuroscience interests. It will also be a cooperative partner of the Swiss Society for Neuroscience.

Ordinary members SFCNS
Swiss Neurological Society SNS | www.swissneuro.ch
Swiss Society of Neurosurgery SSNS | www.swissneurosurgery.ch
Swiss Society of Clinical Neurophysiology | www.sgkn.ch
Swiss Society of Neuropaediatrics SSNP | www.neuropaediatric.ch
Swiss Society of Neuroradiology SSNR | www.swissneuroradiology.ch
Swiss Society of Neuropathology SSNPath | www.ssn.uzh.ch
Swiss Society of Biological Psychiatry SSBP | www.ssbp.ch

Associated members
Swiss Headache Society SHS | www.headache.ch
Swiss Society for Neurorehabilitation SSNRehab | www.sgnr.ch
Swiss Association of Neuropsychology | www.neuropsy.ch
Swiss Society of Behavioural Neurology SSBN | www.sgvn.ch
Swiss Stroke Society SSS | www.neurovasc.ch

Extraordinary members
Swiss League Against Epilepsy SLaE | www.epi.ch
aphasie suisse | www.aphasie.ch

SFCNS Executive Board
President         Prof. Karl Schaller, MD
Vice president   Prof. Philippe Lyrer, MD
Past President   Prof. Anton Valavanis, MD
Secretary | Treasurer  Prof. Barbara Tettenborn, MD
Assessor SSNR    Prof. Jan Gralla, MD
Assessor SSNC    Prof. Andreas Raabe, MD
Assessor SSNP    Prof. Christian Korff, MD
Assessor SSBP    Prof. Martin Hatzinger, MD
Assessor SSCN    Prof. Kai Rösler, MD
General Secretary Harald F. Grossmann

Diamond Partners 2019
We thank the Diamond Partner Companies for their support.